Lancet Publishes Capricor HOPE-3 Data Ahead of Aug. 22 FDA Date
San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) said The Lancet has published results from its Phase 3 HOPE-3 trial, in which Deramiocel slowed upper limb function decline by 54 percent versus placebo in Duchenne muscular dystrophy (PUL 2.0, p=0.03).
The randomized, double-blind, placebo-controlled trial enrolled 106 participants and met its primary endpoint. Capricor also reports a clinically meaningful cardiac benefit. The results rest on the company's prespecified Statistical Analysis Plan version 3.0 (SAP 3.0).